Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Aparna R. Parikh"'
Autor:
Patrice Lazure, Aparna R. Parikh, Neal E. Ready, Marianne J. Davies, Sophie Péloquin, Jeffrey M. Caterino, Robert Lewandowski, Alexander J. Lazar, Suzanne Murray
Publikováno v:
BMC Medical Education, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background The availability of new immuno-oncology therapeutics markedly impacts oncology clinicians’ treatment decision-making. To effectively support healthcare professionals (HCPs) in their practice, it is important to better understand
Externí odkaz:
https://doaj.org/article/3f9fbb6cb5f5446db0637e84ca65a9c4
Autor:
Yousef Khazaei Monfared, Pedram Heidari, Samuel J. Klempner, Umar Mahmood, Aparna R. Parikh, Theodore S. Hong, Matthew R. Strickland, Shadi A. Esfahani
Publikováno v:
Pharmaceutics, Vol 15, Iss 12, p 2761 (2023)
DNA is an organic molecule that is highly vulnerable to chemical alterations and breaks caused by both internal and external factors. Cells possess complex and advanced mechanisms, including DNA repair, damage tolerance, cell cycle checkpoints, and c
Externí odkaz:
https://doaj.org/article/80e7bf35a72b4e689356fed3aede8204
Autor:
Laxmi Upadhyay, Michelle Hartzell, Aparna R. Parikh, Matthew R. Strickland, Samuel Klempner, Midhun Malla
Publikováno v:
Healthcare, Vol 11, Iss 23, p 3010 (2023)
The incidence and mortality of squamous cell carcinoma of the anus (SCCA) is on the rise, which highlights the unmet need for advances in treatment options. The landscape of treatment for this cancer is rapidly evolving with novel combination strateg
Externí odkaz:
https://doaj.org/article/86bd6c5a93e24c5baa39112bbe0c94fb
Autor:
Yousef R. Badran, Justine V. Cohen, Priscilla K. Brastianos, Aparna R. Parikh, Theodore S. Hong, Michael Dougan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background Immune checkpoint inhibitors (ICI) have demonstrated remarkable efficacy as cancer therapeutics, however, their use remains limited due to the development of immune related adverse events (irAEs). Immune related enterocolitis (irE
Externí odkaz:
https://doaj.org/article/ae884ff9b7cc4b2d974df164047ca086
Publikováno v:
Cancers, Vol 14, Iss 13, p 3078 (2022)
Circulating tumor DNA (ctDNA), the tumor-derived cell-free DNA fragments in the bloodstream carrying tumor-specific genetic and epigenetic alterations, represents an emerging novel tool for minimal residual disease (MRD) assessment in patients with r
Externí odkaz:
https://doaj.org/article/45a62db1691949ac8325d1ed95bce34e
Autor:
Sophia C. Kamran, Jeffrey W. Clark, Hui Zheng, Darrell R. Borger, Lawrence S. Blaszkowsky, Jill N. Allen, Eunice L. Kwak, Jennifer Y. Wo, Aparna R. Parikh, Ryan D. Nipp, Janet E. Murphy, Lipika Goyal, Andrew X. Zhu, A. John Iafrate, Ryan B. Corcoran, David P. Ryan, Theodore S. Hong
Publikováno v:
Cancer Medicine, Vol 7, Iss 7, Pp 2934-2942 (2018)
Abstract Recent reports demonstrate inferior outcomes associated with primary right‐sided vs left‐sided colorectal tumors in patients with metastatic colorectal cancer (mCRC). We sought to describe our experience with mCRC patients on whom we hav
Externí odkaz:
https://doaj.org/article/d8d818ceb29849aab15f3fbceae5ca4e
Autor:
Jun Tian, Jonathan H. Chen, Sherry X. Chao, Karin Pelka, Marios Giannakis, Julian Hess, Kelly Burke, Vjola Jorgji, Princy Sindurakar, Jonathan Braverman, Arnav Mehta, Tomonori Oka, Mei Huang, David Lieb, Maxwell Spurrell, Jill N. Allen, Thomas A. Abrams, Jeffrey W. Clark, Andrea C. Enzinger, Peter C. Enzinger, Samuel J. Klempner, Nadine J. McCleary, Jeffrey A. Meyerhardt, David P. Ryan, Matthew B. Yurgelun, Katie Kanter, Emily E. Van Seventer, Islam Baiev, Gary Chi, Joy Jarnagin, William B. Bradford, Edmond Wong, Alexa G. Michel, Isobel J. Fetter, Giulia Siravegna, Angelo J. Gemma, Arlene Sharpe, Shadmehr Demehri, Rebecca Leary, Catarina D. Campbell, Omer Yilmaz, Gad A. Getz, Aparna R. Parikh, Nir Hacohen, Ryan B. Corcoran
Publikováno v:
Nature Medicine. 29:458-466
While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF/MAPK pathway inhibition may augm
Autor:
Zhi Ven Fong, Fidel Lopez Verdugo, Carlos Fernandez-del Castillo, Cristina R Ferrone, Jill N Allen, Lawrence S Blaszkowsky, Jeffrey W Clark, Aparna R Parikh, David P Ryan, Colin D Weekes, Theodore S Hong, Jennifer Y Wo, Keith D Lillemoe, Motaz Qadan
Publikováno v:
Journal of the American College of Surgeons. 236:1126-1136
Autor:
Swati Sonal, Vikram Deshpande, David T. Ting, James C. Cusack, Aparna R. Parikh, Azfar Neyaz, Amaya Pankaj, Martin S. Taylor, Anne M. Dinaux, Lieve G. J. Leijssen, Chloe Boudreau, Joseph J. Locascio, Hiroko Kunitake, Robert N. Goldstone, Liliana G. Bordeianou, Christy E. Cauley, Rocco Ricciardi, David L. Berger
Publikováno v:
Annals of Surgical Oncology. 29:7372-7382
Publikováno v:
Nature Cancer. 3:1420-1422